File Download
  Links for fulltext
     (May Require Subscription)

Article: Treatment with Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) and the Risk of All-Cause Poisoning in Children and Adolescents: A Self-Controlled Case Series Study

TitleTreatment with Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) and the Risk of All-Cause Poisoning in Children and Adolescents: A Self-Controlled Case Series Study
Authors
Issue Date2021
PublisherAdis International Ltd. The Journal's web site is located at https://www.springer.com/journal/40263
Citation
CNS Drugs, 2021, v. 35 n. 7, p. 769-779 How to Cite?
AbstractBackground: Children and adolescents with attention deficit hyperactivity disorder (ADHD) are at higher risk of all-cause poisoning by drugs and chemicals (intentional or accidental). Currently, there is limited data on whether medication treatment for ADHD can reduce the risk of all-cause poisoning. Methods: Patients aged 5–18 years with a methylphenidate (MPH) prescription and an incident poisoning diagnosis between January 2001 and June 2020 were identified from the Hong Kong Clinical Data Analysis and Reporting System. A self-controlled case series study design was used to compare the incidence rate ratios (IRRs) of all-cause poisoning during different risk windows (30 days before the first MPH prescription, exposure periods within 30 days of the first prescription, and periods of subsequent exposure) compared with the reference window (other non-exposure periods). Results: 42,203 patients were prescribed ADHD medication in Hong Kong during the study period. Of these, 417 patients who had both an MPH prescription and poisoning incident recorded were included in the main analysis. Compared with other non-exposed periods, a higher risk of poisoning was found in the 30 days before the first prescription (IRR 2.64, 95% confidence interval [CI] 1.33–5.22) and exposure periods within 30 days of the first prescription (IRR 2.18, 95% CI 1.06–4.48), but not during prolonged exposure. However, compared with 30 days before the first prescription as well as exposure periods within 30 days of the first prescription, there was a lower risk during the subsequent exposure (IRRs 0.49 and 0.60, respectively). Similar results to the main analysis were also found in the subgroup analysis of intentional poisoning and females, but not in that of accidental poisoning and males. Conclusions: The risk of all-cause poisoning was higher shortly before and after the first MPH prescription and became lower during the subsequent prescription period. Our results do not support an association between the use of MPH and an increased risk of all-cause poisoning in children and adolescents and, in fact, suggest that longer-term use of MPH may be associated with a lower risk of all-cause poisoning, although this latter finding requires further study.
Persistent Identifierhttp://hdl.handle.net/10722/305396
ISSN
2023 Impact Factor: 7.4
2023 SCImago Journal Rankings: 1.616
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorGao, L-
dc.contributor.authorMan, KKC-
dc.contributor.authorChan, EW-
dc.contributor.authorChui, CSL-
dc.contributor.authorLi, X-
dc.contributor.authorCoghill, D-
dc.contributor.authorHon, KL-
dc.contributor.authorTse, ML-
dc.contributor.authorLum, TYS-
dc.contributor.authorWong, KHTW-
dc.contributor.authorIp, P-
dc.contributor.authorWong, ICK-
dc.date.accessioned2021-10-20T10:08:49Z-
dc.date.available2021-10-20T10:08:49Z-
dc.date.issued2021-
dc.identifier.citationCNS Drugs, 2021, v. 35 n. 7, p. 769-779-
dc.identifier.issn1172-7047-
dc.identifier.urihttp://hdl.handle.net/10722/305396-
dc.description.abstractBackground: Children and adolescents with attention deficit hyperactivity disorder (ADHD) are at higher risk of all-cause poisoning by drugs and chemicals (intentional or accidental). Currently, there is limited data on whether medication treatment for ADHD can reduce the risk of all-cause poisoning. Methods: Patients aged 5–18 years with a methylphenidate (MPH) prescription and an incident poisoning diagnosis between January 2001 and June 2020 were identified from the Hong Kong Clinical Data Analysis and Reporting System. A self-controlled case series study design was used to compare the incidence rate ratios (IRRs) of all-cause poisoning during different risk windows (30 days before the first MPH prescription, exposure periods within 30 days of the first prescription, and periods of subsequent exposure) compared with the reference window (other non-exposure periods). Results: 42,203 patients were prescribed ADHD medication in Hong Kong during the study period. Of these, 417 patients who had both an MPH prescription and poisoning incident recorded were included in the main analysis. Compared with other non-exposed periods, a higher risk of poisoning was found in the 30 days before the first prescription (IRR 2.64, 95% confidence interval [CI] 1.33–5.22) and exposure periods within 30 days of the first prescription (IRR 2.18, 95% CI 1.06–4.48), but not during prolonged exposure. However, compared with 30 days before the first prescription as well as exposure periods within 30 days of the first prescription, there was a lower risk during the subsequent exposure (IRRs 0.49 and 0.60, respectively). Similar results to the main analysis were also found in the subgroup analysis of intentional poisoning and females, but not in that of accidental poisoning and males. Conclusions: The risk of all-cause poisoning was higher shortly before and after the first MPH prescription and became lower during the subsequent prescription period. Our results do not support an association between the use of MPH and an increased risk of all-cause poisoning in children and adolescents and, in fact, suggest that longer-term use of MPH may be associated with a lower risk of all-cause poisoning, although this latter finding requires further study.-
dc.languageeng-
dc.publisherAdis International Ltd. The Journal's web site is located at https://www.springer.com/journal/40263-
dc.relation.ispartofCNS Drugs-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleTreatment with Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) and the Risk of All-Cause Poisoning in Children and Adolescents: A Self-Controlled Case Series Study-
dc.typeArticle-
dc.identifier.emailChan, EW: ewchan@hku.hk-
dc.identifier.emailChui, CSL: cslchui@hku.hk-
dc.identifier.emailLi, X: sxueli@hku.hk-
dc.identifier.emailLum, TYS: tlum@hku.hk-
dc.identifier.emailWong, KHTW: khtw@hku.hk-
dc.identifier.emailIp, P: patricip@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.authorityChan, EW=rp01587-
dc.identifier.authorityChui, CSL=rp02527-
dc.identifier.authorityLi, X=rp02531-
dc.identifier.authorityLum, TYS=rp01513-
dc.identifier.authorityIp, P=rp01337-
dc.identifier.authorityWong, ICK=rp01480-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1007/s40263-021-00824-x-
dc.identifier.pmid34283391-
dc.identifier.pmcidPMC8310501-
dc.identifier.scopuseid_2-s2.0-85110879643-
dc.identifier.hkuros328194-
dc.identifier.volume35-
dc.identifier.issue7-
dc.identifier.spage769-
dc.identifier.epage779-
dc.identifier.isiWOS:000675046000001-
dc.publisher.placeNew Zealand-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats